
Opinion|Videos|February 7, 2025
Outcomes with Faricimab and Choosing Between the New Therapies
Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- In clinical trials, faricimab showed noninferior vision outcomes compared to aflibercept 2 mg. What added benefit do you see by targeting Ang-2?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The Retina TL;DR: Advancing sustained VEGF suppression with EYP-1901 with Jay S. Duker, MD
2
Frank Holz, MD, FEBO, FARVO, highlights new treatment developments at EURETINA
3
Q&A: The ARCHER trial and the importance of continued GA research
4
Study finds retinal progenitor cell injections improve outcomes in rat model of diabetic retinopathy
5